Last reviewed · How we verify
NCT06036134
Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents
NA trial testing Baseline surveys in Vaccine-Preventable Diseases in 80 participants. Completed in 31 August 2025.
31 August 2025
Quick facts
| Lead sponsor | Arizona State University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 1 December 2023 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Baseline surveys
- Digital Storytelling Intervention
- Information Control Intervention
Conditions studied
- Vaccine-Preventable Diseases — all drugs for Vaccine-Preventable Diseases →
- COVID-19 Pandemic — all drugs for COVID-19 Pandemic →
- Health-Related Behavior — all drugs for Health-Related Behavior →
- Health Knowledge, Attitudes, Practice — all drugs for Health Knowledge, Attitudes, Practice →
Sponsor
Arizona State University
Who can join
18 and older, any sex, with Vaccine-Preventable Diseases or COVID-19 Pandemic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COVID-19 vaccines are available to children over six months, and these vaccines are powerful tools against this catastrophic pandemic. However, Hispanic/Latino children have lower COVID-19 vaccination rates than White non-Hispanic children .Our team of health communication and public health experts proposes a community-based theory-driven intervention that utilizes culturally-grounded narratives from digital storytelling to reduce Hispanic parents' COVID-19 vaccine hesitancy and increase their children's vaccine uptake.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Digital Storytelling to Reduce Hispanic Parents' COVID-19 Vaccine Hesitancy: A Pilot Randomized Controlled Trial.
Kim SW, Lozano F, Todd M, Larkey L, et al · · 2025 · PMID 41295466 · DOI 10.3390/vaccines13111093
Verify or expand the search:
- PubMed search for NCT06036134
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vaccine-Preventable Diseases
Currently open trials in the same condition.
- NCT06978621 — Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV · Phase 3 · recruiting
- NCT06633835 — Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United St · Phase 4 · active not recruiting
- NCT06162676 — Game-Based Intervention to Promote HPV Vaccination · NA · active not recruiting
- NCT06088745 — A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine · Phase 3 · recruiting
- NCT06137755 — Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above · Phase 1 · recruiting
Other Arizona State University trials
Trials by the same sponsor.
- NCT07519408 — Acute Kidney Injury and Ultra-endurance Running · NA · not yet recruiting
- NCT05784467 — Methamphetamine, PrEP, and Intersectional Stigma Study · NA · not yet recruiting
- NCT07375043 — Drumming Groups for Parents of Autistic Children · NA · not yet recruiting
- NCT07297901 — App-based Breathing Program for Migraine Relief · NA · enrolling by invitation
- NCT06721793 — The Impact of a Caffeinated Sports Drink on Performance · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06036134 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arizona State University
- Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06036134.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing